RegeneRx Receives Notice of Intent to Grant Patent in EU for Treating Neural Injury with Thymosin Beta 4

ROCKVILLE, Md., Dec. 16, 2016, RGRX, /PRNewswire/ RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ( the Company or RegeneRx ), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it has received notice of Intent to Grant a patent from the European Patent Office for treating neural injury using Thymosin beta 4 (Tβ4), the active pharmaceutical ingredient in the RegeneRx s proprietary drug candidate, RGN-352. The treatment claims include treating neural injury by remyelinating damaged neurons using Tβ4,
http://bit.ly/2gJTWbg